Fate Therapeutics Stock Options
| FATE Stock | USD 2.96 0.21 6.62% |
Fate Therapeutics' latest option contracts expiring on 2024-12-20 are carrying combined implied volatility of 1.05 with a put-to-call open interest ratio of 0.0 over 12 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2024-12-20. The total put volume is at 149, with calls trading at the volume of 149. This yields a 0.21 put-to-call volume ratio.
Fate Therapeutics' option chain provides insight into all available option contracts written on Fate Therapeutics' stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of Fate Therapeutics' stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given Fate option contract.
In The Money vs. Out of Money Option Contracts on Fate Therapeutics
Analyzing Fate Therapeutics' in-the-money options over time can help investors to take a profitable long position in Fate Therapeutics regardless of its overall volatility. This is especially true when Fate Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Fate Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Fate Therapeutics' stock while costing only a fraction of its price.
Fate Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Fate Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Fate stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Fate Therapeutics' stock price goes up or down, the stock options follow.
At present, Fate Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Sale Purchase Of Stock is expected to grow to about 522.2 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 54.2 M. Fate Therapeutics In The Money Call Balance
When Fate Therapeutics' strike price is surpassing the current stock price, the option contract against Fate Therapeutics stock is said to be in the money. When it comes to buying Fate Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Fate Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Fate Current Options Market Mood
Fate Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Fate Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Fate Therapeutics' options investors are not very successful. Fate Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Fate contract
Base on the Rule 16, the options market is currently suggesting that Fate Therapeutics will have an average daily up or down price movement of about 0.0656% per day over the life of the 2024-12-20 option contract. With Fate Therapeutics trading at USD 2.96, that is roughly USD 0.001943. If you think that the market is fully incorporating Fate Therapeutics' daily price movement you should consider buying Fate Therapeutics options at the current volatility level of 1.05%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Fate |
Purchasing Fate Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Fate calls. Remember, the seller must deliver Fate Therapeutics stock to the call owner when a call is exercised.
Fate Therapeutics Option Chain
When Fate Therapeutics' strike price is surpassing the current stock price, the option contract against Fate Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Fate Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Fate. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Fate. It also shows strike prices and maturity days for a Fate Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Expiration | Current Spread | Last Price | |||
Call | FATE Option Call 20-12-2024 1 | 0 | 2024-12-20 | 0.0 - 0.0 | 1.16 | In |
Call | FATE Option Call 20-12-2024 2 | 0 | 2024-12-20 | 0.0 - 0.0 | 1.12 | In |
Call | FATE Option Call 20-12-2024 3 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.51 | |
Call | FATE Option Call 20-12-2024 4 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.22 | |
Call | FATE Option Call 20-12-2024 5 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.25 | |
Call | FATE Option Call 20-12-2024 6 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.2 | |
Put | FATE Option Put 20-12-2024 1 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.05 | |
Put | FATE Option Put 20-12-2024 2 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.1 | |
Put | FATE Option Put 20-12-2024 3 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.35 | In |
Put | FATE Option Put 20-12-2024 4 | 0 | 2024-12-20 | 0.0 - 0.0 | 1.4 | In |
Put | FATE Option Put 20-12-2024 5 | 0 | 2024-12-20 | 0.0 - 4.0 | 2.44 | In |
Put | FATE Option Put 20-12-2024 6 | 0 | 2024-12-20 | 0.0 - 0.0 | 3.3 | In |
Fate Therapeutics Market Cap Over Time
Market Cap |
| Timeline |
Fate Total Stockholder Equity
Total Stockholder Equity |
|
Fate Therapeutics Corporate Management
| Barbara Hickingbottom | Senior Development | Profile | |
| Andrew Henry | Senior Operations | Profile | |
| YuWaye MD | Chief Officer | Profile | |
| Cindy Tahl | General Secretary | Profile | |
| Edward III | Chief Officer | Profile | |
| Bahram Valamehr | Chief Development Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.123 | Quarterly Revenue Growth 0.581 | Return On Assets (0.22) | Return On Equity (0.47) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.